Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 11
Phase 21

Trial Status

Other2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT05315258Phase 2Active Not Recruiting
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
Melanoma (Skin)Melanoma, Uveal
PrincipalinvestigatorStart date: 2022-07-25
NCT04852367Phase 1Withdrawn
PanDox: Targeted Doxorubicin in Pancreatic Tumours
Pancreatic Cancer MetastaticPancreatic Cancer Non-resectablePancreatic Cancer Stage IV+1 more
PrincipalinvestigatorStart date: 2021-06-16

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Consultant Medical Oncologist and Professor of Experimental Cancer Medicine

Similar Key Opinion Leaders

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT05315258Phase 2PrincipalInvestigator

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Melanoma (Skin)Melanoma, Uveal
Active Not Recruiting
NCT04852367Phase 1PrincipalInvestigator

PanDox: Targeted Doxorubicin in Pancreatic Tumours

Pancreatic Cancer MetastaticPancreatic Cancer Non-resectablePancreatic Cancer Stage IV+1 more
Withdrawn

All 2 trials loaded